Penetrium Bioscience Receives MFDS Approval for Amendment to Phase 1 Combination Trial with Pembrolizumab in Refractory Solid Tumors - Manufacturing and Formulation Changes, No Immediate Capital Impact
Penetrium Bioscience obtained approval from the Korean MFDS for a clinical trial plan amendment regarding its Phase 1 combination study of pembrolizumab and PenetriumTM in patients with refractory solid tumors conducted at Ajou University Hospital.
The amendment primarily involves changes to the manufacturing site and formulation; trial objectives and design remain unchanged, focusing on maximum tolerated dose and dose-limiting toxicity.
This disclosure does not involve any capital raising or share issuance, thus having no immediate dilutive effect on existing shareholders. Trial results are expected around June 2028.
[AI Summary]Penetrium Bioscience's amendment approval for its Phase 1 solid tumor combination trial is an operational milestone with no direct impact on equity or capital structure. Investors should consider the approximately 10% statistical probability of eventual drug approval as a key risk factor.
KOSDAQ Filing Information
Key Management Matters Related to Investment Decision (Approval of Clinical Trial Plan Amendment) (Approval of Amendment to Phase 1 Clinical Trial Plan of Pembrolizumab and PenetriumTM Combination Therapy for Refractory/Recurrent Solid Tumors)